Clinical trials: Myeloid and Monocytic Leukemia
Leukemia, Myeloid
Physical Activity as Self-Management Approach to Improve Health Outcomes in AML
Physical Activity as a Self-Management Approach to Improve Health Outcomes in Acute Myeloid Leukemia
- Conditions
- Leukemia, Myeloid, Monocytic
- Trial name
- NCT02584296
- Testing
- BSMA
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Virginia Commonwealth University
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
This phase I/II trial is studying the side effects and best dose of tipifarnib when given with idarubicin and cytarabine and to see how well it works in treating patients with newly diagnosed myelodysplastic syndromes or acute…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00096122
- Testing
- cytarabine, idarubicin, tipifarnib
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
This phase II trial studies the effect of CPX-351 followed by donor stem cell transplantation versus immediate donor stem cell transplantation in treating patients with high-grade myeloid cancers with measurable residual disease.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm
- Trial name
- NCT04526288
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing.
- Trial name
- NCT00003405
- Testing
- recombinant interferon alfa, amifostine trihydrate, bromodeoxyuridine
- Where
- 4 sites in United States
- Sponsor
- Rush University Medical Center
Leukemia
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002588
- Testing
- etoposide, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia
Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01251159
- Testing
- mutation analysis, polymerase chain reaction, immunologic technique
- Volunteers
- 30 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Leukemia
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002768
- Testing
- filgrastim, busulfan, cytarabine
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Leukemia
Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01169363
- Testing
- proteomic profiling, flow cytometry, laboratory biomarker analysis
- Volunteers
- 200 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
AML Therapy With Irradiated Allogeneic Cells
This pilot clinical trial studies if cells donated by a close genetic relative can help maintain acute myeloid leukemia (AML) complete remission (CR). Eligible patients will receive a standard induction chemotherapy.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT02105116
- Testing
- fludarabine phosphate, cytarabine, donor lymphocytes
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Rutgers, The State University of New Jersey
Adult Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission
This phase II trial studies how well fludarabine and busulfan followed by a donor (allogeneic) stem cell transplant work in treating older patients with acute myeloid leukemia that is in first complete remission.
- Trial name
- NCT00070135
- Testing
- filgrastim, Anti-Thymocyte Globulin, busulfan
- Where
- 21 sites in United States
- Volunteers
- 121 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Leukemia
S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and tissue from patients with cancer treated with cytarabine in the laboratory may help doctors learn more about the effects of cytarabine on cells.
- Trial name
- NCT01338974
- Testing
- gene expression analysis, proteomic profiling, flow cytometry
- Volunteers
- 290 people
- Sponsor
- SWOG Cancer Research Network
Leukemia
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00814164
- Testing
- clofarabine, daunorubicin hydrochloride, cytogenetic analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Monocytic, Acute, Pediatric AML
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
This is a multicenter, single arm, prospective, intervention trial. Since cladribine can enhance the biological activity and self-protection of cytarabine, giving cladribine and cytarabine together may kill more cancer cells.
- Trial name
- SCCLG-M5 (NCT05313958)
- Testing
- Cladribine, G-CSF, Cytarabine
- Where
- 9 sites in China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
This phase I trial studies the side effects and best dose of a chemotherapy regimen given by continuous intravenous infusion (CI-CLAM), and to see how well it works in treating patients with acute myeloid leukemia that has come…
- Conditions
- Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04196010
- Testing
- Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Washington
Leukemia
Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003178
- Testing
- filgrastim, cladribine, idarubicin
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 120 people
- Sponsor
- Children's Oncology Group
Leukemia
Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- AML1107 (NCT00775593)
- Testing
- clofarabine, temsirolimus
- Where
- 19 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
This phase II trial is studying the side effects of giving azacitidine together with gemtuzumab ozogamicin to see how well it works in treating older patients with previously untreated acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia
- Trial name
- NCT00658814
- Testing
- Azacitidine, Gemtuzumab Ozogamicin
- Where
- 177 sites in United States
- Volunteers
- 133 people
- Sponsor
- National Cancer Institute (NCI)
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PSC 833 may increase the effectiveness of chemotherapy by making cancer cells more sensitive to the drugs.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7)
- Trial name
- NCT00006363
- Testing
- cytarabine, daunorubicin hydrochloride, etoposide
- Where
- United States
- Volunteers
- 720 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
RATIONALE: Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop cancer cells from dividing so they stop growing and die.
- Trial name
- NCT00085709
- Testing
- gemtuzumab ozogamicin, observation, Cytosine arabinoside
- Where
- 279 sites in United States, Canada and 1 more
- Volunteers
- 637 people
- Sponsor
- SWOG Cancer Research Network
Leukemia
Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)
The purpose of this study is to find out the maximum tolerated dose (MTD) of the combined therapy of lenalidomide (Revlimid®) and Granulocyte/macrophage colony stimulating factor and CD40 Ligand expressed in the K562 cell line…
- Trial name
- NCT00840931
- Testing
- lenalidomide, bystander vaccine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute